Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Sees Large Drop in Short Interest

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) saw a large drop in short interest in the month of September. As of September 30th, there was short interest totaling 13,700 shares, a drop of 44.8% from the September 15th total of 24,800 shares. Based on an average trading volume of 32,600 shares, the short-interest ratio is currently 0.4 days. Based on an average trading volume of 32,600 shares, the short-interest ratio is currently 0.4 days.

Emmaus Life Sciences Price Performance

Shares of EMMA opened at $0.01 on Tuesday. The firm has a 50-day moving average of $0.01 and a 200-day moving average of $0.01. Emmaus Life Sciences has a one year low of $0.00 and a one year high of $0.05. The company has a market cap of $593,991.00, a PE ratio of -0.09 and a beta of 8.03.

Emmaus Life Sciences (OTCMKTS:EMMA) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.02) EPS for the quarter. The firm had revenue of $2.82 million for the quarter.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.